Company Overview and News

30
Market Update: Realty, infra stocks gain ahead of RBI policy; Lupin, Sun Pharma up 1-2%

2018-06-06 moneycontrol
The broader indices are trading on a negative note this Wednesday morning ahead of the RBI monetary policy which is scheduled later in the day. The Nifty is trading higher by 15 points at 10,608 and the Sensex gained 52 points at 34,955.
524715 533150 533096 GREENFIRE 512573 532714 532712 BHRQY 532832 533278 ABAN JUSTDIAL 535648 532187 RCOM HDFCBANK BHARTIARTL KEC CLNDY 503100 YESBANK PHOENIXLTD AVANTI INDUSINDBK 590057 IBN 532648 YYBKY 532454 500380 ICICIBANK GODREJPROP HDB 532174 500180 SUNPHARMA 534809 ADANIPOWER JKLAKSHMI PCJEWELLER 523204 COALINDIA JSTQY IBREALEST

0
JK Lakshmi Cement Limited - Updates

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

31
Market Live: Sensex falls 100 pts as Brent crude inches up towards $80/bbl

2018-05-17 moneycontrol
Market Update: The market is reeling under pressure with the Sensex falling 100 points as investors after digesting Karnataka election outcome started monitoring earnings, and movement in rupee and crude oil prices.
MUTHOOTFIN DVSLY BHRYY 500325 590003 500228 RELIANCE BRIGADE 530239 533398 SUVEN 532343 500470 GRANULES 532482 CENTURYPLY 534816 CAREERP RIGD HDFCBANK INFRATEL 500570 TATAMOTORS RLNIY 532929 TVSMOTOR 533260 IBN 532548 JSWSTEEL 500380 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 JKLAKSHMI KARURVYSYA TTM

31
Market Live: Sensex, Nifty mildly lower; RIL, HDFC, Infosys, metals stocks drag

2018-05-17 moneycontrol
Crude Update: Oil prices firmed, with Brent crude creeping ever closer to USD 80 per barrel, a level it has not seen since November 2014, as supplies tighten while demand remains strong.
MUTHOOTFIN DVSLY BHRYY 500325 590003 500228 RELIANCE BRIGADE 533398 532343 500470 GRANULES 532482 CENTURYPLY 534816 CAREERP RIGD HDFCBANK INFRATEL 500570 TATAMOTORS RLNIY 532929 TVSMOTOR 533260 IBN 532548 JSWSTEEL 500380 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 JKLAKSHMI KARURVYSYA TTM

28
Market Live: Sensex, Nifty off opening highs; all sectoral indices in the green barring metals

2018-05-17 moneycontrol
Buzzing: Tata Steel saw profit booking after opening higher as it reported a consolidated net profit of Rs 14,688 crore for the March quarter, as against a loss of Rs 1,168 crore in the same quarter last year, benefiting from a one-time gain of Rs 11,376.14 crore from the restructuring of its UK business' pension scheme.
MUTHOOTFIN DVSLY 590003 500228 BRIGADE 533398 532343 500470 GRANULES 532482 CENTURYPLY CAREERP HDFCBANK 500570 TATAMOTORS 532929 TVSMOTOR 533260 IBN 532548 JSWSTEEL 500380 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 JKLAKSHMI KARURVYSYA TTM

0
JK Lakshmi Cement Q4 profit jumps 62% to Rs34 crore

2018-05-16 livemint
New Delhi: JK Lakshmi Cement on Wednesday reported 62.30% surge in its standalone net profit to Rs33.84 crore for the fourth quarter ended 31 March 2018.
500380 JKLAKSHMI

0
JK Lakshmi Cement Limited - Raising of Funds

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

0
JK Lakshmi Cement Limited - Financial Result Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

0
JK Lakshmi Cement Limited - Outcome of Board Meeting

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

0
JK Lakshmi Cement Limited - Dividend

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

0
JK Lakshmi Cement Limited - Press Release

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

0
JK Lakshmi Cement Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500380 JKLAKSHMI

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...